4
Changes in Ownership
Prelude Therapeutics Inc Filed Acc 0001562180-23-001170
Options or other derivatives
- Chief Scientific Officer acquired 135,000 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Scherle Peggy Chief Scientific Officer | 2023-02-07 | Grant or award · Employee Stock Option (right to buy) | +135,000 | 135,000 | D: show line 1 in the form |
Loading xslF345X03/primarydocument.xml…